Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11831907rdf:typepubmed:Citationlld:pubmed
pubmed-article:11831907lifeskim:mentionsumls-concept:C0132555lld:lifeskim
pubmed-article:11831907lifeskim:mentionsumls-concept:C0030011lld:lifeskim
pubmed-article:11831907lifeskim:mentionsumls-concept:C0038477lld:lifeskim
pubmed-article:11831907lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:11831907lifeskim:mentionsumls-concept:C0063140lld:lifeskim
pubmed-article:11831907pubmed:issue4lld:pubmed
pubmed-article:11831907pubmed:dateCreated2002-2-8lld:pubmed
pubmed-article:11831907pubmed:abstractTextThe formation of nitric oxide (NO) was followed during the oxidation of 37 N-hydroxyguanidines or related derivatives, including 18 new N-aryl N'-hydroxyguanidines, by recombinant inducible nitric oxide synthase (NOS II). Several N-aryl N'-hydroxyguanidines bearing a relatively small, electron-donating para subtituent, such as H, F, Cl, CH(3), OH, OCH(3), and NH(2), led to NO formation rates between 8 and 41% of that of NO formation from the natural NOS substrate, N(omega)-hydroxy-L-arginine (NOHA). The characteristics of these reactions were very similar to those previously reported for the oxidation of NOHA by NOS:(i) the strict requirement of NOS containing (6R)-5,6,7,8-tetrahydro-L-biopterin, reduced nicotinamide adenine dinucleotide phosphate, and O(2) for the oxidation to occur, (ii) the formation of NO and the corresponding urea in a 1:1 molar ratio, and (iii) a strong inhibitory effect of the classical NOS inhibitors such as N(omega)-nitro-L-arginine and S-ethyl-iso-thiourea. Structure-activity relationship studies showed that two structural factors are crucial for NO formation from compounds containing a C(triple bond)NOH function. The first one is the presence of a monosubstituted N-hydroxyguanidine function, since disubstituted N-hydroxyguanidines, amidoximes, ketoximes, and aldoximes failed to produce NO. The second one is the presence of a N-phenyl ring bearing a relatively small, not electron-withdrawing para substituent that could favorably interact with a hydrophobic cavity close to the NOS catalytic site. The k(cat) value for NOS II-catalyzed oxidation of N-para-fluorophenyl N'-hydroxyguanidine was 80% of that found for NOHA, and its k(cat)/K(m) value was only 9-fold lower than that of NOHA. Interestingly, the K(m) value found for NOS II-catalyzed oxidation of N-(3-thienyl) N'-hydroxyguanidine was 25 microM, almost identical to that of NOHA. Recombinant NOS I and NOS III also oxidize several N-aryl N'-hydroxyguanidines with the formation of NO, with a clearly different substrate specificity. The best substrates of the studied series for NOS I and NOS III were N-(para-hydroxyphenyl) and N-(meta-aminophenyl) N'-hydroxyguanidine, respectively. Among the studied compounds, the para-chlorophenyl and para-methylphenyl derivatives were selective substrates of NOS II. These results open the way toward a new class of selective NO donors after in situ oxidation by each NOS family.lld:pubmed
pubmed-article:11831907pubmed:languageenglld:pubmed
pubmed-article:11831907pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11831907pubmed:citationSubsetIMlld:pubmed
pubmed-article:11831907pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11831907pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11831907pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11831907pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11831907pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11831907pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11831907pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11831907pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11831907pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11831907pubmed:statusMEDLINElld:pubmed
pubmed-article:11831907pubmed:monthFeblld:pubmed
pubmed-article:11831907pubmed:issn0022-2623lld:pubmed
pubmed-article:11831907pubmed:authorpubmed-author:Renodon-Corni...lld:pubmed
pubmed-article:11831907pubmed:authorpubmed-author:DijolsSylvieSlld:pubmed
pubmed-article:11831907pubmed:authorpubmed-author:PerollierCéli...lld:pubmed
pubmed-article:11831907pubmed:authorpubmed-author:Lefevre-Grobo...lld:pubmed
pubmed-article:11831907pubmed:authorpubmed-author:BoucherJean-L...lld:pubmed
pubmed-article:11831907pubmed:authorpubmed-author:AttiasRogerRlld:pubmed
pubmed-article:11831907pubmed:authorpubmed-author:SariMarie-Agn...lld:pubmed
pubmed-article:11831907pubmed:authorpubmed-author:StuehrDennisDlld:pubmed
pubmed-article:11831907pubmed:authorpubmed-author:MansuyDanielDlld:pubmed
pubmed-article:11831907pubmed:issnTypePrintlld:pubmed
pubmed-article:11831907pubmed:day14lld:pubmed
pubmed-article:11831907pubmed:volume45lld:pubmed
pubmed-article:11831907pubmed:ownerNLMlld:pubmed
pubmed-article:11831907pubmed:authorsCompleteYlld:pubmed
pubmed-article:11831907pubmed:pagination944-54lld:pubmed
pubmed-article:11831907pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11831907pubmed:meshHeadingpubmed-meshheading:11831907...lld:pubmed
pubmed-article:11831907pubmed:meshHeadingpubmed-meshheading:11831907...lld:pubmed
pubmed-article:11831907pubmed:meshHeadingpubmed-meshheading:11831907...lld:pubmed
pubmed-article:11831907pubmed:meshHeadingpubmed-meshheading:11831907...lld:pubmed
pubmed-article:11831907pubmed:meshHeadingpubmed-meshheading:11831907...lld:pubmed
pubmed-article:11831907pubmed:meshHeadingpubmed-meshheading:11831907...lld:pubmed
pubmed-article:11831907pubmed:meshHeadingpubmed-meshheading:11831907...lld:pubmed
pubmed-article:11831907pubmed:meshHeadingpubmed-meshheading:11831907...lld:pubmed
pubmed-article:11831907pubmed:meshHeadingpubmed-meshheading:11831907...lld:pubmed
pubmed-article:11831907pubmed:meshHeadingpubmed-meshheading:11831907...lld:pubmed
pubmed-article:11831907pubmed:meshHeadingpubmed-meshheading:11831907...lld:pubmed
pubmed-article:11831907pubmed:meshHeadingpubmed-meshheading:11831907...lld:pubmed
pubmed-article:11831907pubmed:meshHeadingpubmed-meshheading:11831907...lld:pubmed
pubmed-article:11831907pubmed:meshHeadingpubmed-meshheading:11831907...lld:pubmed
pubmed-article:11831907pubmed:year2002lld:pubmed
pubmed-article:11831907pubmed:articleTitleN-Aryl N'-hydroxyguanidines, a new class of NO-donors after selective oxidation by nitric oxide synthases: structure-activity relationship.lld:pubmed
pubmed-article:11831907pubmed:affiliationLaboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR 8601 CNRS, Université Paris V, 45 Rue des Saints Pères, 75270 Paris Cedex 06, France.lld:pubmed
pubmed-article:11831907pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11831907pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11831907pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:11831907lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11831907lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11831907lld:pubmed